

Gianpaolo Reboldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7122204/publications.pdf>

Version: 2024-02-01

269
papers

14,086
citations

36203

51
h-index

23472

111
g-index

289
all docs

289
docs citations

289
times ranked

12808
citing authors

#	ARTICLE	IF	CITATIONS
1	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1501-1509.	0.8	9
2	Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e149-e152.	0.8	11
3	Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations. <i>European Journal of Internal Medicine</i> , 2022, 95, 7-12.	1.0	10
4	Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 235-242.	0.9	10
5	Dipping pattern and short-term blood pressure variability are stronger predictors of cardiovascular events than average 24-h blood pressure in young hypertensive subjects. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1377-1386.	0.8	14
6	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1245-1252.	1.1	15
7	Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy. <i>European Journal of Heart Failure</i> , 2022, 24, 855-860.	2.9	8
8	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis. <i>European Journal of Internal Medicine</i> , 2022, 101, 49-55.	1.0	9
9	Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes. <i>Hypertension</i> , 2022, 79, 1028-1036.	1.3	2
10	Tight Blood Pressure Control in Chronic Kidney Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 139.	0.8	3
11	Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 150.	0.8	16
12	Vitamin E (Alpha-Tocopherol) Metabolism and Nutrition in Chronic Kidney Disease. <i>Antioxidants</i> , 2022, 11, 989.	2.2	25
13	Intensive blood pressure control and cognitive impairment in chronic kidney disease: The jury is still out. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0
14	COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the "Spike effect". <i>European Journal of Internal Medicine</i> , 2022, 103, 23-28.	1.0	32
15	Safety of catheter ablation of atrial fibrillation in cancer survivors. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 419-426.	0.6	20
16	Masked Nocturnal Hypertension: A Complex Phenomenon to Detect in Clinical Practice. <i>American Journal of Hypertension</i> , 2021, 34, 578-580.	1.0	2
17	Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey. <i>Journal of Nephrology</i> , 2021, 34, 325-335.	0.9	11
18	The Link Between Inflammation and Hypertension: Unmasking Mediators. <i>American Journal of Hypertension</i> , 2021, 34, 683-685.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021, 397, 1625-1636.	6.3	414
20	Ageing, ACE2 deficiency and bad outcome in COVID-19. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1607-1609.	1.4	15
21	SARS-CoV-2 vaccines: Lights and shadows. <i>European Journal of Internal Medicine</i> , 2021, 88, 1-8.	1.0	90
22	Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. <i>Cardiology and Therapy</i> , 2021, 10, 397-406.	1.1	15
23	Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion. <i>Kidney Medicine</i> , 2021, 3, 619-634.	1.0	18
24	SARS-CoV-2 infection and ACE2 inhibition. <i>Journal of Hypertension</i> , 2021, 39, 1555-1558.	0.3	15
25	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021, 398, 1053-1064.	6.3	133
26	The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later. <i>European Journal of Internal Medicine</i> , 2021, 93, 28-34.	1.0	40
27	African Ancestry and Uncontrolled Hypertension: Current Knowledge and Future Perspectives. <i>American Journal of Hypertension</i> , 2021, 34, 1255-1258.	1.0	1
28	Lessons Learnt during the COVID-19 Pandemic: For Patients with End-Stage Renal Disease, We Should Prioritize Home-Based Treatment and Telemedicine. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 1-6.	0.9	10
29	Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". <i>Journal of Nephrology</i> , 2020, 33, 9-35.	0.9	73
30	Hypertensive urgencies and emergencies: Misconceptions and pitfalls. <i>European Journal of Internal Medicine</i> , 2020, 71, 15-17.	1.0	7
31	Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 229-238.	1.0	3
32	Association of Extreme Nocturnal Dipping With Cardiovascular Events Strongly Depends on Age. <i>Hypertension</i> , 2020, 75, 324-330.	1.3	38
33	Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2123-2132.	1.1	9
34	RAAS Inhibitors and Risk of Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 1990-1994.	13.9	21
35	Performance of creatinine- and cystatin C-based formulas to estimate glomerular filtration rate. <i>European Journal of Internal Medicine</i> , 2020, 80, 16-17.	1.0	1
36	The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations. <i>European Journal of Internal Medicine</i> , 2020, 82, 1-6.	1.0	53

#	ARTICLE	IF	CITATIONS
37	Management of hypertension in the very old: an intensive reduction of blood pressure should be achieved in most patients. <i>Journal of Human Hypertension</i> , 2020, 34, 551-556.	1.0	2
38	Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus. <i>Journal of Hypertension</i> , 2020, 38, 1190-1191.	0.3	25
39	The revolution of the anti-diabetic drugs in cardiology. <i>European Heart Journal Supplements</i> , 2020, 22, E162-E166.	0.0	2
40	Blood pressure variability and risk of stroke in chronic kidney disease. <i>Journal of Hypertension</i> , 2020, 38, 599-602.	0.3	7
41	Treatment strategies for isolated systolic hypertension in elderly patients. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1713-1723.	0.9	6
42	Electrocardiographic features of patients with COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2020, 78, 101-106.	1.0	111
43	Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. <i>Journal of Nephrology</i> , 2020, 33, 725-736.	0.9	79
44	Microalbuminuria assessment after thoracic surgery: Early identification of complication risks. <i>Clinical Respiratory Journal</i> , 2020, 14, 564-570.	0.6	2
45	Use of Antibiotics and Mortality in Women. <i>Circulation Research</i> , 2020, 126, 374-376.	2.0	1
46	Optimal Use of the Non-Inferiority Trial Design. <i>Pharmaceutical Medicine</i> , 2020, 34, 159-165.	1.0	14
47	Detrimental Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: New Insights from Umbria Atrial Fibrillation Registry. <i>Medicina (Lithuania)</i> , 2019, 55, 358.	0.8	3
48	Response by Verdecchia et al to Letter Regarding Article "Sudden Cardiac Death in Hypertensive Patients". <i>Hypertension</i> , 2019, 74, HYPERTENSIONAHA11913441.	1.3	0
49	Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study. <i>TH Open</i> , 2019, 03, e157-e164.	0.7	1
50	Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 1127-1150.	1.1	85
51	European and US guidelines for arterial hypertension: similarities and differences. <i>European Journal of Internal Medicine</i> , 2019, 63, 3-8.	1.0	20
52	Added predictive value of high uric acid for cardiovascular events in the Ambulatory Blood Pressure International Study. <i>Journal of Clinical Hypertension</i> , 2019, 21, 966-974.	1.0	9
53	Electrocardiography for diagnosis of left ventricular hypertrophy in hypertensive patients with atrial fibrillation. <i>International Journal of Cardiology: Hypertension</i> , 2019, 1, 100004.	2.2	3
54	Tight Blood Pressure Control Saves Lives in Hypertensive Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2019, 73, 1172-1173.	1.3	2

#	ARTICLE	IF	CITATIONS
55	Sudden Cardiac Death in Hypertensive Patients. <i>Hypertension</i> , 2019, 73, 1071-1078.	1.3	38
56	Managing hypertension in 2018: which guideline to follow?. <i>Heart Asia</i> , 2019, 11, e011127.	1.1	12
57	Echocardiography in Low-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2019, 8, e013497.	1.6	14
58	Short-term blood pressure variability outweighs average 24-h blood pressure in the prediction of cardiovascular events in hypertension of the young. <i>Journal of Hypertension</i> , 2019, 37, 1419-1426.	0.3	37
59	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the Atrial Fibrillation Registry Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010107.	1.6	17
60	PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 533-541.	1.5	4
61	Hypertension and Atrial Fibrillation. <i>Circulation Research</i> , 2018, 122, 352-368.	2.0	151
62	Left Ventricular Hypertrophy and Coronary Artery Calcifications: A Dangerous Duet?. <i>American Journal of Hypertension</i> , 2018, 31, 287-289.	1.0	7
63	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation: the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , 2018, 20, 253-262.	0.7	11
64	Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes. <i>Kidney International</i> , 2018, 93, 195-203.	2.6	64
65	A18644 Echocardiography in Low-Risk Hypertensive Patients. When is it needed?. <i>Journal of Hypertension</i> , 2018, 36, e187.	0.3	0
66	Keep Blood Pressure Low, but Not Too Much. <i>Circulation Research</i> , 2018, 123, 1205-1207.	2.0	10
67	Gathering evidence on the prognostic role of central blood pressure in hypertension. <i>Hypertension Research</i> , 2018, 41, 865-868.	1.5	3
68	Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1073-1084.	1.3	19
69	GLOMERULAR HYPERFILTRATION IS AN INDEPENDENT PREDICTOR OF ADVERSE CARDIOVASCULAR EVENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i330-i330.	0.4	0
70	RENAL FUNCTION IS RELATED TO INCREASED THROMBOEMBOLIC AND BLEEDING RISK IN PATIENTS WITH ATRIAL FIBRILLATION IN A REAL-WORLD SETTING: THE UMBRIA-FA STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i17-i17.	0.4	0
71	What to Do When Blood Pressure Is Between 130/80 and 139/89 mmHg?. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1198-1200.	1.2	2
72	The 2018 ESC/ESH hypertension guidelines: Should nephrologists always stop at the lower boundary?. <i>Journal of Nephrology</i> , 2018, 31, 621-626.	0.9	13

#	ARTICLE	IF	CITATIONS
73	Heart failure, pulse pressure and heart rate. <i>International Journal of Cardiology</i> , 2018, 271, 206-208.	0.8	7
74	Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. <i>Journal of Human Hypertension</i> , 2018, 32, 625-632.	1.0	6
75	Hypertensive Heart Disease. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 189-212.	0.1	0
76	How Low Should We Go With Blood Pressure?. <i>Circulation Research</i> , 2017, 120, 27-29.	2.0	6
77	How important is to reduce sodium and increase potassium in patients with hypertension?. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e54-e57.	0.6	0
78	Masked tachycardia. A predictor of adverse outcome in hypertension. <i>Journal of Hypertension</i> , 2017, 35, 487-492.	0.3	22
79	Intensive Blood Pressure Lowering and Regression of Left Ventricular Hypertrophy. <i>Circulation</i> , 2017, 136, 451-453.	1.6	3
80	The Tale of an Innocent. <i>Circulation</i> , 2017, 136, 2230-2232.	1.6	4
81	Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	13
82	Echo and BNP serial assessment in ambulatory heart failure care: Data on loop diuretic use and renal function. <i>Data in Brief</i> , 2016, 9, 1074-1076.	0.5	2
83	Home blood pressure and treatment decisions. <i>Journal of Hypertension</i> , 2016, 34, 1494-1496.	0.3	0
84	Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients. <i>International Journal of Cardiology</i> , 2016, 224, 416-423.	0.8	26
85	Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 1462-1471.	2.9	41
86	Prognostic Value of Ambulatory Blood Pressure in the Obese: The Ambulatory Blood Pressure International Study. <i>Journal of Clinical Hypertension</i> , 2016, 18, 111-118.	1.0	6
87	More Versus Less Intensive Blood Pressure Lowering Strategy. <i>Hypertension</i> , 2016, 68, 642-653.	1.3	75
88	Does Malaria Cause Hypertension?. <i>Circulation Research</i> , 2016, 119, 7-9.	2.0	5
89	Why switch from warfarin to NOACs?. <i>Internal and Emergency Medicine</i> , 2016, 11, 289-293.	1.0	35
90	Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients. <i>Hypertension</i> , 2016, 67, 693-700.	1.3	399

#	ARTICLE	IF	CITATIONS
91	Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation. <i>Endocrine</i> , 2016, 52, 571-578.	1.1	25
92	Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0147601.	1.1	882
93	The prognostic legacy of left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2015, 33, 2322-2330.	0.3	22
94	Twenty-four hour ambulatory blood pressure monitoring to all? Comments to the US Preventive Services Task Force document. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 911-915.	2.3	6
95	Cardiac Benefits of an Intensive Blood Pressure Control in Diabetes Mellitus. <i>Hypertension</i> , 2015, 66, 1104-1105.	1.3	1
96	Prevalence of Patent Foramen Ovale in Ischaemic Stroke in Italy: Results of SISIFO Study. <i>Cerebrovascular Diseases</i> , 2015, 39, 162-169.	0.8	22
97	Enhancing the Benefit of Bivalirudin in Percutaneous Coronary Intervention: Is High Risk of Bleeding the Key?. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 221-224.	1.0	1
98	Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015, 9, 412-424.	1.0	50
99	Interpretation of ambulatory blood pressure profile. <i>Journal of Hypertension</i> , 2015, 33, 454-457.	0.3	13
100	Prognostic impact of sex-specific ambulatory blood pressure interactions in 10 cohorts of 17,312 patients diagnosed with hypertension. <i>Journal of Hypertension</i> , 2015, 33, 212-220.	0.3	23
101	The SPRINT trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 750-753.	2.3	5
102	The 2014 hypertension guidelines: implications for patients and practitioners in Asia. <i>Heart Asia</i> , 2015, 7, 21-25.	1.1	17
103	Masked and White-Coat Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2170-2172.	1.2	2
104	Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease. <i>Hypertension</i> , 2015, 65, 108-114.	1.3	70
105	Left Ventricular Hypertrophy and Obesity: Only a Matter of Fat?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 29-41.	1.0	35
106	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 7-20.	1.0	23
107	Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 1164-1173.	1.1	2
108	Safety of Dabigatran in an Elderly Population: Single Center Experience in Italy. <i>Current Drug Safety</i> , 2015, 10, 165-169.	0.3	5

#	ARTICLE	IF	CITATIONS
109	Microalbuminuria as a predictor of cardiopulmonary complications after thoracic surgery. , 2015, , .		1
110	Aggressive Blood Pressure Lowering Is Dangerous: The J-Curve. Hypertension, 2014, 63, 37-40.	1.3	53
111	Interpretation of Ambulatory Blood Pressure Profile for Risk Stratification. Hypertension, 2014, 63, 913-914.	1.3	14
112	Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. Expert Review of Cardiovascular Therapy, 2014, 12, 623-634.	0.6	19
113	Hypertension, inflammation and atrial fibrillation. Journal of Hypertension, 2014, 32, 480-483.	0.3	42
114	Tight Versus Standard Blood Pressure Control in Patients With Hypertension With and Without Cardiovascular Disease. Hypertension, 2014, 63, 475-482.	1.3	31
115	Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus, 2014, 23, 743-751.	0.8	34
116	Cardiovascular risk assessment in low-resource settings. Journal of Hypertension, 2014, 32, 951-960.	0.3	73
117	Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13â€844 patients with hypertension. Journal of Hypertension, 2014, 32, 2332-2340.	0.3	222
118	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). American Journal of Cardiology, 2014, 113, 669-675.	0.7	14
119	Clinical Implications. Hypertension, 2014, 63, 4-4.	1.3	24
120	Endoscopic biopsy samples of naÃve â€colitidesâ€patients: Role of basal plasmacytosis. Journal of Crohn's and Colitis, 2014, 8, 1438-1443.	0.6	28
121	Risk and decision making in patients with hypertension. Lancet, The, 2014, 384, 562-564.	6.3	4
122	Ambulatory blood pressure monitoring in the elderly: Features and perspectives. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1052-1056.	1.1	8
123	Added Predictive Value of Night-Time Blood Pressure Variability for Cardiovascular Events and Mortality. Hypertension, 2014, 64, 487-493.	1.3	156
124	Usefulness of QRS Voltage Correction by Body Mass Index to Improve Electrocardiographic Detection of Left Ventricular Hypertrophy in Patients With Systemic Hypertension. American Journal of Cardiology, 2014, 114, 427-432.	0.7	28
125	Contribution of the ABP-International study to the definition of night-time tachycardia. Journal of Hypertension, 2014, 32, 2099-2100.	0.3	3
126	Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons. PLoS ONE, 2014, 9, e100478.	1.1	24

#	ARTICLE	IF	CITATIONS
127	Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians. <i>Current Drug Safety</i> , 2014, 9, 106-117.	0.3	10
128	Multivariable Analysis in Cerebrovascular Research: Practical Notes for the Clinician. <i>Cerebrovascular Diseases</i> , 2013, 35, 187-193.	0.8	23
129	Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. <i>International Journal of Cardiology</i> , 2013, 168, 1490-1495.	0.8	73
130	Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 379-385.	1.5	20
131	Protein intake in type 1 diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1086-1090.	0.3	1
132	Effects of a Multidisciplinary Lifestyle Intervention for Obesity on Mental and Physical Components of Quality of Life: The Mediatory Role of Depression. <i>Psychological Reports</i> , 2013, 112, 33-46.	0.9	17
133	Parental Alliance and Family Functioning in Pediatric Obesity from Both Parents' Perspectives. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2013, 34, 583-588.	0.6	7
134	Hypertension around the world. <i>Journal of Hypertension</i> , 2013, 31, 1358-1361.	0.3	14
135	Response to Morning Surge, Dipping, and Sleep-Time Blood Pressure as Prognostic Markers of Cardiovascular Risk. <i>Hypertension</i> , 2013, 61, .	1.3	2
136	The "Echo Heart Failure Score"™: an echocardiographic risk prediction score of mortality in systolic heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 868-876.	2.9	64
137	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	4.3	20
138	Modernization and hypertension: is the link changing?. <i>Hypertension Research</i> , 2013, 36, 676-678.	1.5	4
139	Hypertension and the J-curve phenomenon: implications for tight blood pressure control. <i>Hypertension Research</i> , 2013, 36, 109-111.	1.5	21
140	Response to Body Position and Quality of Sleep Interfere With Day-Night Blood Pressure Dip. <i>Hypertension</i> , 2012, 60, .	1.3	0
141	Response to Do Extreme Dippers Have a Lower Cardiovascular Risk Than Dippers?. <i>Hypertension</i> , 2012, 60, .	1.3	0
142	"From Apennines to Andes": Does Body Mass Index Affect the Relationship Between Age and Blood Pressure?. <i>Hypertension</i> , 2012, 60, 6-7.	1.3	8
143	Above Which Blood Pressure Level Does the Risk of Atrial Fibrillation Increase?. <i>Hypertension</i> , 2012, 59, 184-185.	1.3	12
144	Response to Role of Yin and Yang in Diurnal Blood Pressure Variation for Cardiovascular Disease. <i>Hypertension</i> , 2012, 60, .	1.3	0

#	ARTICLE	IF	CITATIONS
145	Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions. <i>Current Drug Safety</i> , 2012, 7, 76-85.	0.3	20
146	Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. <i>Hypertension Research</i> , 2012, 35, 17-19.	1.5	2
147	Response to Is Vascular Morning Blood Pressure Surge in the Elderly Resistant to Antihypertensives and More Risky?. <i>Hypertension</i> , 2012, 60, .	1.3	0
148	Day-Night Dip and Early-Morning Surge in Blood Pressure in Hypertension. <i>Hypertension</i> , 2012, 60, 34-42.	1.3	264
149	Intensive blood pressure control in obese diabetic patients: clinical relevance of stroke prevention in the ACCORD trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1467-1470.	0.6	6
150	Blood pressure lowering in diabetic patients. <i>Journal of Hypertension</i> , 2012, 30, 438-439.	0.3	7
151	Echocardiographic left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2012, 30, 2279-2284.	0.3	3
152	Microcirculation and left-ventricular hypertrophy. <i>Journal of Hypertension</i> , 2012, 30, 477-481.	0.3	8
153	Statins in acute coronary syndrome: very early initiation and benefits. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 163-174.	1.0	20
154	Very early initiation of statin therapy and mortality in patients with acute coronary syndrome. <i>Acute Cardiac Care</i> , 2012, 14, 34-39.	0.2	10
155	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. <i>Italian Journal of Medicine</i> , 2012, 6, 302-306.	0.2	0
156	Fixed-Dose Combination Therapy in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012, 19, 51-54.	1.0	15
157	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 81-91.	1.0	39
158	Mutual Interactions between Depression/Quality of Life and Adherence to a Multidisciplinary Lifestyle Intervention in Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2261-E2265.	1.8	39
159	Safety and efficacy of aliskiren in the treatment of hypertension: a systematic overview. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 659-670.	1.0	16
160	Atrial Fibrillation and Mortality in Patients with Acute Myocardial Infarction: A Systematic Overview and Meta-analysis. <i>Current Cardiology Reports</i> , 2012, 14, 601-610.	1.3	55
161	Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. <i>Current Cardiology Reports</i> , 2012, 14, 89-96.	1.3	21
162	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. <i>Diabetologia</i> , 2012, 55, 36-45.	2.9	56

#	ARTICLE	IF	CITATIONS
163	Fixed-Dose Combination Therapy in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 51-54.	1.0	10
164	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 115-128.	1.5	10
165	More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertension. Hypertension Research, 2011, 34, 445-447.	1.5	5
166	Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Review of Clinical Pharmacology, 2011, 4, 151-161.	1.3	21
167	Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets. Journal of Hypertension, 2011, 29, 173-175.	0.3	0
168	Lowering blood pressure with β^2 -blockers in peripheral artery disease: the importance of comorbidity. Journal of Hypertension, 2011, 29, 1298-1302.	0.3	0
169	Clinical Significance of the Blood Pressure Changes from Day to Night. Current Hypertension Reviews, 2011, 7, 13-19.	0.5	2
170	Emerging therapies in the management of hypertensive patients with osteoarthritis. Clinical Investigation, 2011, 1, 125-136.	0.0	1
171	Simplifying the ECG Diagnosis of Left Ventricular Hypertrophy. Current Cardiovascular Risk Reports, 2011, 5, 1-4.	0.8	1
172	Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. Current Atherosclerosis Reports, 2011, 13, 176-185.	2.0	16
173	Good news for beta-blockers in perioperative medicine. Expert Opinion on Drug Safety, 2011, 10, 491-498.	1.0	3
174	Modern treatment of patients at risk: still a HOPE for ACE inhibitors?. Expert Opinion on Pharmacotherapy, 2011, 12, 839-843.	0.9	5
175	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 415-423.	3.1	28
176	Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. Journal of Hypertension, 2011, 29, 1253-1269.	0.3	235
177	Neutrophil Count and Ambulatory Pulse Pressure as Predictors of Cardiovascular Adverse Events in Postmenopausal Women with Hypertension. American Journal of Hypertension, 2011, 24, 591-598.	1.0	25
178	Hypertensive disorders during pregnancy. Journal of Hypertension, 2011, 29, 2320-2323.	0.3	21
179	Diuretic Treatment of Hypertension. Diabetes Care, 2011, 34, S313-S319.	4.3	38
180	Fluid and electrolyte balance after major thoracic surgery by bioimpedance and endocrine evaluation. European Journal of Cardio-thoracic Surgery, 2011, 40, e71-6.	0.6	12

#	ARTICLE	IF	CITATIONS
181	Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. <i>Journal of Hypertension</i> , 2010, 28, 1356-1365.	0.3	69
182	New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis. <i>Current Diabetes Reviews</i> , 2010, 6, 102-110.	0.6	37
183	Blood pressure lowering in the oldest old. <i>Journal of Hypertension</i> , 2010, 28, 1373-1376.	0.3	13
184	Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 159-164.	0.8	1
185	The Optimal Blood Pressure Target for Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2010, 12, 302-306.	1.3	12
186	Aliskiren versus ramipril in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 193-200.	1.0	23
187	Î²-blockers and risk of all-cause mortality in non-cardiac surgery. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 109-118.	1.0	7
188	“The Lower the BP the Better” Paradigm in the Elderly. <i>Hypertension</i> , 2010, 56, 182-184.	1.3	10
189	Angiotensin receptor blockers in hypertension. New insights from Japan. <i>Hypertension Research</i> , 2010, 33, 394-397.	1.5	8
190	Is Hydrochlorothiazide More Effective on LVH in Nonresponders to Losartan Than in Those to Atenolol?. <i>American Journal of Hypertension</i> , 2010, 23, 705-705.	1.0	1
191	Neutrophil Count for the Identification of Postmenopausal Hypertensive Women at Increased Cardiovascular Risk. <i>Obstetrics and Gynecology</i> , 2010, 115, 695-703.	1.2	12
192	Î²-Blockers Reduce Mortality in Patients Undergoing High-Risk Non-Cardiac Surgery. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 247-259.	1.0	36
193	Masked Hypertension: Evaluation, Prognosis, and Treatment. <i>American Journal of Hypertension</i> , 2010, 23, 941-948.	1.0	88
194	Electrocardiographic abnormalities of left ventricular repolarization: Prognostic implications in hypertensive post-menopausal women. <i>Maturitas</i> , 2010, 67, 159-165.	1.0	5
195	Treatment strategies for osteoarthritis patients with pain and hypertension. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 229-240.	1.2	15
196	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?. <i>Current Vascular Pharmacology</i> , 2010, 8, 742-746.	0.8	12
197	Comparative assessment of angiotensin receptor blockers in different clinical settings. <i>Vascular Health and Risk Management</i> , 2009, 5, 939.	1.0	14
198	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. <i>Vascular Health and Risk Management</i> , 2009, 5, 411.	1.0	39

#	ARTICLE	IF	CITATIONS
199	Good News from Aliskiren?. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2862.	0.1	0
200	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2009, 54, 188-195.	1.3	56
201	Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1349-1361.	0.6	12
202	Effect of revascularizing viable myocardium on left ventricular diastolic function in patients with ischaemic cardiomyopathy. <i>European Heart Journal</i> , 2009, 30, 1501-1509.	1.0	38
203	The emerging role of high-density lipoprotein cholesterol in hypertension trials. <i>Journal of Hypertension</i> , 2009, 27, 458-460.	0.3	3
204	Perioperative β^2 blockade: the debate continues. <i>Lancet, The</i> , 2009, 373, 627.	6.3	5
205	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet, The</i> , 2009, 374, 525-533.	6.3	391
206	Cardiovascular effects of tight versus usual blood-pressure control – Authors' reply. <i>Lancet, The</i> , 2009, 374, 1742.	6.3	1
207	The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2009, 27, 1697-1704.	0.3	44
208	Response to Home Blood Pressure Measurements Will or Will Not Replace 24-Hour Ambulatory Blood Pressure Measurement. <i>Hypertension</i> , 2009, 54, .	1.3	4
209	Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 417-419.	0.8	0
210	Prognostic value of circadian blood pressure changes in relation to differing measures of day and night. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 88-96.	2.3	15
211	The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 1-3.	1.0	1
212	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1171-1174.	0.6	2
213	Optimizing the definition of dippers and nondippers: is a 70% full glass empty?. <i>Journal of Hypertension</i> , 2008, 26, 630-632.	0.3	3
214	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. <i>European Heart Journal</i> , 2008, 30, 679-688.	1.0	66
215	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. <i>Journal of Hypertension</i> , 2008, 26, 1282-1289.	0.3	121
216	Is the definition of daytime and nighttime blood pressure prognostically relevant?. <i>Blood Pressure Monitoring</i> , 2008, 13, 153-155.	0.4	21

#	ARTICLE	IF	CITATIONS
217	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 971-981.	1.0	76
218	Response to Why Is Nondipping in Ambulatory Blood Pressure Monitoring Not Prognostic in Poor Sleepers?. <i>Hypertension</i> , 2007, 50, .	1.3	0
219	New-Onset Diabetes, Antihypertensive Treatment, and Outcome. <i>Hypertension</i> , 2007, 50, 459-460.	1.3	20
220	Ambulatory Blood Pressure and Cardiovascular Outcome in Relation to Perceived Sleep Deprivation. <i>Hypertension</i> , 2007, 49, 777-783.	1.3	116
221	The clinical significance of white-coat and masked hypertension. <i>Blood Pressure Monitoring</i> , 2007, 12, 387-389.	0.4	52
222	Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension. <i>American Journal of Hypertension</i> , 2007, 20, 154-161.	1.0	156
223	Prognostic Value of Serial Electrocardiographic Voltage and Repolarization Changes in Essential Hypertension: The HEART Survey Study. <i>American Journal of Hypertension</i> , 2007, 20, 997-1004.	1.0	39
224	Patients With Hibernating Myocardium Show Altered Left Ventricular Volumes and Shape, Which Revert After Revascularization. <i>Journal of the American College of Cardiology</i> , 2006, 47, 969-977.	1.2	116
225	Regression of Left Ventricular Hypertrophy and Prevention of Stroke in Hypertensive Subjects. <i>American Journal of Hypertension</i> , 2006, 19, 493-499.	1.0	60
226	A Reviewer Critique of Microalbuminuria and Cardiovascular Risk Assessment in Primary Hypertension: Should Threshold Levels Be Revised?. <i>American Journal of Hypertension</i> , 2006, 19, 735-736.	1.0	0
227	Is the Development of Diabetes With Antihypertensive Therapy a Problem?â€”Pro. <i>Journal of Clinical Hypertension</i> , 2006, 8, 120-126.	1.0	7
228	White-coat hypertension in adults. <i>Blood Pressure Monitoring</i> , 2005, 10, 301-305.	0.4	50
229	New-onset diabetes in treated hypertensive patients. <i>Current Hypertension Reports</i> , 2005, 7, 174-179.	1.5	28
230	Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. <i>Hypertension</i> , 2005, 46, 386-392.	1.3	317
231	Short- and Long-Term Incidence of Stroke in White-Coat Hypertension. <i>Hypertension</i> , 2005, 45, 203-208.	1.3	271
232	Do angiotensin II receptor blockers increase the risk of myocardial infarction?. <i>European Heart Journal</i> , 2005, 26, 2381-2386.	1.0	54
233	Prognostic value of lipoprotein fractions in essential hypertension. <i>Blood Pressure</i> , 2004, 13, 295-303.	0.7	8
234	Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. <i>Hypertension</i> , 2004, 43, 963-969.	1.3	476

#	ARTICLE	IF	CITATIONS
235	Meta-Analysis of effectiveness or lack thereof of Angiotensin-Converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. <i>American Journal of Cardiology</i> , 2004, 93, 240-243.	0.7	28
236	Hypertension and microalbuminuria: the new detrimental duo. <i>Blood Pressure</i> , 2004, 13, 198-211.	0.7	36
237	Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. <i>American Journal of Hypertension</i> , 2004, 17, 817-822.	1.0	65
238	Validation of the A&D UA-774 (UA-767Plus) device for self-measurement of blood pressure. <i>Blood Pressure Monitoring</i> , 2004, 9, 225-229.	0.4	26
239	Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. <i>Journal of Hypertension</i> , 2004, 22, 407-414.	0.3	31
240	Risk of stroke in white-coat hypertension: a multinational registry. <i>American Journal of Hypertension</i> , 2003, 16, A65.	1.0	0
241	Improved cardiovascular risk stratification by a simple ECG index in hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 646-652.	1.0	59
242	Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. <i>European Journal of Endocrinology</i> , 2003, 148, 505-513.	1.9	42
243	Atrial Fibrillation in Hypertension. <i>Hypertension</i> , 2003, 41, 218-223.	1.3	289
244	Left ventricular mass and systolic dysfunction in essential hypertension. <i>Journal of Human Hypertension</i> , 2002, 16, 117-122.	1.0	20
245	Change in cardiovascular risk profile by echocardiography in low- or medium-risk hypertension. <i>Journal of Hypertension</i> , 2002, 20, 1519-1525.	0.3	47
246	Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. <i>Journal of the American College of Cardiology</i> , 2002, 39, 878-885.	1.2	133
247	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. <i>Diabetologia</i> , 2002, 45, 1362-1371.	2.9	33
248	Optimizing assessment of carotid and femoral intima-media thickness in essential hypertension. <i>American Journal of Hypertension</i> , 2001, 14, 1025-1031.	1.0	8
249	Left Ventricular Hypertrophy as an Independent Predictor of Acute Cerebrovascular Events in Essential Hypertension. <i>Circulation</i> , 2001, 104, 2039-2044.	1.6	249
250	High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. <i>Journal of Hypertension</i> , 2001, 19, 2265-2270.	0.3	47
251	Ambulatory monitoring for prediction of cardiac and cerebral events. <i>Blood Pressure Monitoring</i> , 2001, 6, 211-215.	0.4	11
252	Prognostic value of midwall shortening fraction and its relation with left ventricular mass in systemic hypertension. <i>American Journal of Cardiology</i> , 2001, 87, 479-482.	0.7	22

#	ARTICLE	IF	CITATIONS
253	Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2001, 38, 371-376.	2.1	225
254	High-Normal Serum Creatinine Concentration Is a Predictor of Cardiovascular Risk in Essential Hypertension. <i>Archives of Internal Medicine</i> , 2001, 161, 886.	4.3	149
255	Different Prognostic Impact of 24-Hour Mean Blood Pressure and Pulse Pressure on Stroke and Coronary Artery Disease in Essential Hypertension. <i>Circulation</i> , 2001, 103, 2579-2584.	1.6	216
256	Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: a case-control study. <i>Blood Pressure Monitoring</i> , 2000, 5, 187-193.	0.4	15
257	Subclinical left ventricular dysfunction in systemic hypertension and the role of 24-hour blood pressure. <i>American Journal of Cardiology</i> , 2000, 86, 509-513.	0.7	18
258	Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension. <i>Hypertension</i> , 2000, 36, 1072-1078.	1.3	480
259	Circulating Insulin and Insulin Growth Factor-1 Are Independent Determinants of Left Ventricular Mass and Geometry in Essential Hypertension. <i>Circulation</i> , 1999, 100, 1802-1807.	1.6	172
260	Value of a simple echocardiographic linear predictor of left ventricular mass in systemic hypertension. <i>American Journal of Cardiology</i> , 1999, 84, 1209-1214.	0.7	9
261	Prognostic Significance of Serial Changes in Left Ventricular Mass in Essential Hypertension. <i>Circulation</i> , 1998, 97, 48-54.	1.6	583
262	Moderate and Large Doses of Ethanol Differentially Affect Hepatic Protein Metabolism in Humans. <i>Journal of Nutrition</i> , 1998, 128, 198-203.	1.3	26
263	Nicotinamide Counteracts Alcohol-Induced Impairment of Hepatic Protein Metabolism in Humans. <i>Journal of Nutrition</i> , 1997, 127, 2199-2204.	1.3	17
264	Pharmacokinetic Profile and Endocrine Effects of Posatirelin Treatment in Healthy Elderly Subjects. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 823-831.	1.0	1
265	Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. <i>American Journal of Cardiology</i> , 1996, 78, 197-202.	0.7	147
266	Dexamethasone suppression test in elderly patients with dementia of Alzheimer type, vascular dementia and stroke: a re-evaluation of its applicability. <i>Archives of Gerontology and Geriatrics</i> , 1995, 21, 205-214.	1.4	3
267	Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. <i>Journal of the American College of Cardiology</i> , 1995, 25, 871-878.	1.2	375
268	Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension.. <i>Hypertension</i> , 1994, 24, 793-801.	1.3	1,564
269	Aggressive blood pressure reduction in patients at high vascular risk: is it dangerous?. <i>Italian Journal of Medicine</i> , 0, , .	0.2	0